Fox Run Management’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Fox Run Management’s Portfolio KDNY Stock Details KDNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-13,437	Closed	-$311K	–	1038
2023 Q1	$311K	Buy	13,437 +5,701	+74%	+$136K	0.1%	391
2022 Q4	$203K	Sell	7,736 -11,830	-60%	-$262K	0.08%	484
2022 Q3	$385K	Buy	+19,566	New	+$392K	0.15%	264
2018 Q3	–	Sell	-4,946	Closed	-$173K	–	882
2018 Q2	$173K	Buy	4,946 +436	+10%	+$16.7K	0.05%	594
2018 Q1	$210K	Sell	4,510 -45	-1%	-$1.65K	0.05%	615
2017 Q4	$171K	Buy	4,555 +2,175	+91%	+$95K	0.05%	597
2017 Q3	$127K	Buy	+2,380	New	+$141K	0.04%	635
2017 Q2	–	Sell	-3,760	Closed	-$202K	–	880
2017 Q1	$202K	Buy	+3,760	New	+$212K	0.08%	492
2016 Q4	–	Sell	-2,800	Closed	-$174K	–	717
2016 Q3	$174K	Buy	+2,800	New	+$198K	0.1%	414

Other funds holding KDNY

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fox Run Management's KDNY Position: Q2 2023 in Review

Fox Run Management sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q2 2023, closing a stake of 13,437 shares — an estimated $311K sold.

Fox Run Management first reported a position in KDNY in Q3 2016 and held it in 9 quarters. The position peaked at $385K in Q3 2022. 185 funds tracked by Wall St. Rank hold KDNY as of Q2 2023.

Fox Run Management reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Fox Run Management sold 13,437 Chinook Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $311K.
Fox Run Management first reported a position in Chinook Therapeutics, Inc. Common Stock in Q3 2016 and held it in 9 quarters.
Fox Run Management's Chinook Therapeutics, Inc. Common Stock position peaked at $385K in Q3 2022.
185 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Fox Run Management's 13F filing for Q2 2023, filed 11 Aug 2023.